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Aims Inflammation has important roles in atherosclerosis. CD4þCD28null (CD28null) T cells are a specialized T lympho-
cyte subset that produce inflammatory cytokines and cytotoxic molecules. CD28null T cells expand preferentially in
patients with acute coronary syndrome (ACS) rather than stable angina and are barely detectable in healthy sub-
jects. Importantly, ACS patients with CD28null T-cell expansion have increased risk for recurrent acute coronary
events and poor prognosis, compared to ACS patients in whom this cell subset does not expand. The mechanisms
regulating CD28null T-cell expansion in ACS remain elusive. We therefore investigated the role of cytokines in




High-purity sorted CD4þ T cells from ACS patients were treated with a panel of cytokines (TNF-a, IL-1b, IL-6, IL-
7, and IL-15), and effects on the number, phenotype, and function of CD28null T cells were analysed and compared
to the control counterpart CD28þ T-cell subset. IL-7- and IL-15-induced expansion of CD28null T cells from ACS
patients, while inflammatory cytokines TNF-a, IL-1b, and IL-6 did not. The mechanisms underlying CD28null T-cell
expansion by IL-7/IL-15 were preferential activation and proliferation of CD28null T cells compared to control
CD28þ T cells. Additionally, IL-7/IL-15 markedly augmented CD28null T-cell cytotoxic function and interferon-c
production. Further mechanistic analyses revealed differences in baseline expression of component chains of IL-7/
IL-15 receptors (CD127 and CD122) and increased baseline STAT5 phosphorylation in CD28null T cells from ACS
patients compared to the control CD28þ T-cell subset. Notably, we demonstrate that CD28null T-cell expansion
was significantly inhibited by Tofacitinib, a selective JAK1/JAK3 inhibitor that blocks IL-7/IL-15 signalling.
....................................................................................................................................................................................................
Conclusion Our novel data show that IL-7 and IL-15 drive the expansion and function of CD28null T cells from ACS patients
suggesting that IL-7/IL-15 blockade may prevent expansion of these cells and improve patient outcomes.
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1. Introduction
Coronary artery disease (CAD) and acute coronary syndrome
(ACS) remain a major cause of death and morbidity worldwide
despite considerable advances in diagnosis, prevention, and treat-
ment.1 T lymphocytes have pivotal roles in atherosclerosis and
pathogenesis of CAD.2,3 CD4þCD28null (CD28null) T cells are an
inflammatory subset of T lymphocytes defined by the lack of the
co-stimulatory receptor CD28. CD28null T cells are unique as they
are not present in mice but have been identified exclusively in
humans with chronic inflammatory diseases.4,5 These cells preferen-
tially expand in the circulation and atherosclerotic plaques of
patients with ACS rather than stable angina,6,7 and are nearly
undetectable in healthy individuals.4,8 Importantly, ACS patients
with expansion of CD28null T cells have increased risk for recur-
rent acute coronary events and poor prognosis compared to ACS
patients in whom this subset does not expand.9 Moreover, in-
creased CD28null T cells are an independent predictor of future
acute coronary events in ACS patients.9 We have previously dem-
onstrated that in contrast to the conventional control
CD4þCD28þ (CD28þ) T-cell subset, CD28null T cells from ACS
patients produce high levels of inflammatory cytokines tumour ne-
crosis factor-a (TNF-a) and interferon-c (IFN-c) and release cyto-
toxic molecules (perforin and granzyme B) that could harm the
vascular wall by promoting inflammation and plaque rupture.10 We
showed that co-stimulatory receptors OX40 and 4-1BB modulate
CD28null T-cell function and that co-stimulation blockade reduced
the inflammatory and cytotoxic actions of these cells.10 We have
also identified that CD28null T cells from ACS patients have
defects in proteasomal degradation of pro-apoptotic mole-
cules.5,11,12 However, the precise mechanisms that regulate
CD28null T-cell expansion in ACS patients are yet to be
deciphered.
Inflammatory cytokines such as TNF-a, interleukin-1b (IL-1b), and IL-6
have important roles in driving inflammation in CAD patients.3,13–15
Recently, the CANTOS trial showed that targeted cytokine inhibition (IL-
1b inhibition with Canakinumab) in CAD patients with a prior myocardial
infarction and residual inflammatory risk reduced further cardiovascular
events.16 Other cytokines that are deregulated in chronic inflammatory
diseases (e.g. rheumatoid arthritis, RA) and are currently targeted in
patients are IL-7 and IL-15 that belong to the common gamma chain cyto-
kine family.17–19 Whether these cytokines are involved in the expansion
and function of CD28null T cells in ACS patients is unknown.
Here, we provide novel evidence that the cytokines IL-7 and IL-15
trigger CD28null T-cell expansion in ACS patients, while inflammatory
cytokines (TNF-a, IL-1b, and IL-6) do not. IL-7- and IL-15-induced pref-
erential activation and proliferation of CD28null T cells and promoted
their cytotoxic and inflammatory function. We dissect the mechanistic
basis of IL-7 and IL-15 effects on CD28null T cells from ACS patients and
demonstrate that Tofacitinib, a selective JAK1/JAK3 inhibitor that blocks
IL-7/IL-15 signalling, significantly inhibits CD28null T-cell expansion.
These new data suggest that targeting IL-7 and IL-15 could potentially
provide a therapeutic strategy to prevent expansion of CD28null T cells
in ACS patients.
Graphical Abstract
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Peripheral blood was collected from patients with ACS (Supplementary
material online, Tables S1 and S2; samples collected <12 h from chest
pain) admitted at the coronary care unit, St. George’s Hospital NHS
Trust, London. Patients with malignancies, infectious diseases, autoim-
mune disorders, on treatment with anti-inflammatory drugs except aspi-
rin, or over 80 years old were excluded from the study, as previously
described.10,11 The study conformed to the Declaration of Helsinki prin-
ciples (study approved by the London & Chelsea Research Ethics
Committee, REC 09/H0801/27), and written informed consent was
obtained from all study participants prior to inclusion in the study.
2.2 Flow cytometry
The frequency of CD28null T cells in fresh peripheral blood samples (cir-
culating CD28null T cells) was determined by staining 100mL blood with
CD4-FITC and CD28-APC (BD Biosciences), followed by red blood
cells lysis with Lyse/Fix buffer (BD Biosciences), as previously de-
scribed.10 The percentage of circulating CD28null T cells was calculated
as the percentage of CD4þ T cells, as previously described.10 The gating
strategy for quantification of CD28null T cells in fresh peripheral blood
samples and cultured peripheral blood mononuclear cells (PBMCs) or
CD4þ T cells is depicted in Supplementary material online, Figure S1.
Where indicated, CD127-PE (Invitrogen), CD122-PE, CD132-PE,
CD215-PE (all BioLegend) were added to fresh peripheral blood sam-
ples stained with CD4-FITC and CD28-APC. The following monoclonal
antibodies were used to identify CD28null T cells in cultured samples and
analyse the expression of functional markers on CD28null and CD28þ T
cells: CD4-FITC, CD28-APC, CD28-PE, HLA-DR-APC, CXCR3-PE,
CCR7-PE, CD45RO-FITC, TNF-a-PE-Cy7 (all BD Biosciences/BD
Pharmingen); CD14-PE (Miltenyi Biotec); CD69-APC, CD215-PE,
CD45RA-PE-Cy7 (all Biolegend); CD62L-APC, Granzyme B-PE, IFN-c-
APC (all eBioscience); CCR5-PE, CD127-PE (all Invitrogen). Intracellular
levels of IFN-c and TNF-a were quantified in sorted CD4þ T cells cul-
tured alone or with IL-7 or IL-15 for 3 days following 4 h stimulation of
with phorbol myristate acetate, ionomycin, and brefeldin, as previously
described.6,7,10 Dead cells were excluded from the analysis by staining
with 7-aminoactinomycin D (7-AAD, BD Biosciences) or, for intracellu-
lar staining (i.e. granzyme-B, IFN-c, and TNF-a), by labelling with
ZombieYellow (Biolegend) or Fixable viability stain 575 V (BD
Biosciences) prior to fixation and permeabilization using Cytofix/
Cytoperm (BD Biosciences). Phosphorylated STAT5 was assessed via
the BD Phosflow method using CD4-H7, CD28-APC, Alexa Fluor 488
anti-STAT5, Alexa Fluor 488 mouse IgG1 j isotype control, BD Cytofix
buffer, and BD Perm Buffer III (all BD Biosciences) as per the manufac-
turer’s instructions. Samples were acquired on a FACSCalibur (BD
Biosciences) or Navios (Beckman Coulter) flow cytometer and data
were analysed using FlowJo software v7.6 (FlowJo, LLC). Mean fluores-
cence intensity (MFI) was calculated by subtracting the MFI of samples
stained with isotype control antibodies from the MFI of samples stained
with antibodies against specific markers. The percentage increase in
CD28null T cells following cytokine treatment was calculated as:
100(%CD28null in treated samples-%CD28null in untreated samples)/
%CD28null in untreated samples.
2.3 Cell isolation and culture
Peripheral blood mononuclear cells were isolated from fresh blood sam-
ples by density gradient centrifugation as described previously.11 CD4þ
T cells were purified by magnetic separation using negative selection kits
from Miltenyi Biotec and Invitrogen (MagniSort) as per the manufac-
turers’ instructions. CD4þ T cells were cultured at 2105 cells per well
in U-bottom 96-well plates in RPMI1640 (Life Technologies) containing
100 U/mL penicillin, 100mg/mL streptomycin, and 15 mM L-glutamine
(Sigma-Aldrich), supplemented with 5% pooled human AB serum
(Corning). Cells were stimulated with the indicated concentrations of re-
combinant human cytokines (IL-1b, IL-6, IL-7, IL-15, TNF-a; R&D
Systems) and cultured for up to 11 days. Where indicated, cells were
stimulated with IL-7/IL-15 in the presence or absence of 100 nM
Tofacitinib (CP 690550 citrate, Tocris Bioscience). Where indicated, cul-
ture supernatant from CD4þ T cells stimulated with IL-7, IL-15, and un-
stimulated cells were collected and kept frozen until quantification of
TNF-a and IFN-c by DuoSet ELISA (R&D Systems), as per the manufac-
turer’s instructions.
2.4 Proliferation assay
Sorted CD4þ T cells were labelled with 1mM carboxyfluorescein succi-
nimidyl ester (CFSE, Invitrogen) and cultured in the presence of IL-7 or
IL-15 as indicated. Proliferation (assessed as CFSE dilution) was quanti-
fied by flow cytometry following staining with antibodies (CD4-APC-H7,
CD28-APC) and dead cell exclusion with 7-AAD (all BD Biosciences).
2.5 Degranulation assay
2105 CD4þ T cells were cultured alone or stimulated with 50 ng/mL
IL-7 or IL-15 for 4 days. Four hours before analysis, CD107a-PE (BD
Biosciences) was added to the culture and cells were either left un-
stimulated or stimulated with 2mg/mL functional grade anti-human CD3
monoclonal antibody (Invitrogen); BD GolgiStop (BD Biosciences) was
added for the last 3 h of culture. Cells were then stained with CD4-
FITC, CD28-APC, and 7-AAD (BD Biosciences) and CD107a expres-
sion was quantified by flow cytometry.
2.6 Quantification of plasma cytokine levels
Plasma was separated from fresh EDTA-treated blood samples from
ACS patients and stored frozen until quantification of IL-7, IL-15, TNF-a,
IL-1b, and IL-6 by DuoSet ELISA (R&D Systems) and by IL-7 and IL-15
Quantikine high sensitivity ELISA (R&D Systems).
2.7 Statistics
Statistical analysis was performed using GraphPad Prism v7.02 and v8.4.
Cytokine-treated and untreated samples were compared using paired
two-tailed Student’s t-test or two-tailed Wilcoxon matched-pairs
signed-rank test as indicated. For comparison of more than two groups,
statistical significance was determined using one- or two-way analysis of
variance (ANOVA) and Bonferroni post-test for multiple comparisons.
Plasma cytokine levels in the two study groups were compared using
two-tailed Mann–Whitney test. Categorical data were analysed with the
v2 test. Probability (P) values of <0.05 were considered statistically
significant.
2.8 Study approval
The study conformed to the Declaration of Helsinki principles (study ap-
proved by the London & Chelsea Research Ethics Committee, REC 09/
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..H0801/27), and written informed consent was obtained from all study
participants prior to inclusion in the study.
3. Results
3.1 Inflammatory cytokines TNF-a, IL-1b,
and IL-6 do not induce expansion of
CD28null T cells from ACS patients
To investigate the role of inflammatory cytokines (TNF-a, IL-1b, IL-6) in
CD28null T lymphocyte expansion in ACS, we analysed cells from
patients without expansion of the CD28null T-cell subset defined as <2%
circulating CD28null T cells out of all CD4þ T cells in peripheral blood
(quantified as detailed in Methods and Supplementary material online,
Figure S1A).6,7,10 PBMCs from ACS patients were cultured alone or in
the presence of cytokines for up to 7 days. The percentage of CD28null T
cells remained unchanged following TNF-a, IL-1b, or IL-6 treatment at
all concentrations and time points tested (Supplementary material on-
line, Figure S2). Similar results were observed with high-purity sorted
CD4þ T cells treated with TNF-a, IL-1b, or IL-6, which did not affect
CD28null T-cell percentage (Supplementary material online, Figure S3).
Combinations of inflammatory cytokines (i.e. TNF-aþIL-1b, TNF-aþIL-
6, IL-1bþIL-6, and TNF-aþIL-1bþIL-6) had no effect on CD28null T cells
(Supplementary material online, Figure S4). To further investigate
whether inflammatory cytokines have any effect on CD28null T cells, we
tested these cytokines on PBMCs (Supplementary material online, Figure
S5A–C) or high-purity sorted CD4þ T cells (Supplementary material on-
line, Figure S5D–F) from ACS patients with pre-existing CD28null T-cell
expansion in peripheral blood, that is, >3% circulating CD28null T cells
(detailed in Methods and Supplementary material online, Figure
S1A).6,7,10 In all samples tested TNF-a, IL-1b, or IL-6 did not affect
CD28null T-cell percentage, indicating that these inflammatory cytokines
are unlikely to contribute to CD28null T-cell expansion in ACS patients.
3.2 IL-7 and IL-15 trigger expansion of
CD28null T cells from ACS patients
As inflammatory cytokines did not affect the number of CD28null T cells,
we sought whether other cytokines drive expansion of this subset. We
focused on IL-7 and IL-15, which belong to the common gamma chain
cytokine family as they are involved in the pathogenesis of chronic in-
flammatory disorders and are targeted in patients with autoimmune dis-
orders.17 PBMCs or high-purity sorted CD4þ T cells from ACS patients
with >3% circulating CD28null T cells were treated with IL-7 and IL-15.
CD28null T-cell percentage increased significantly on days 4 and 7 of cul-
ture (PBMC: Figure 1A–C, Supplementary material online, Figure S6A–D;
CD4þ T cells: Figure 1D–F, Supplementary material online, Figure S6E and
F). Combinations of IL-7 and IL-15 did not have synergistic effects on
CD28null T-cell expansion (not shown).
We also examined whether IL-7 and IL-15 expand CD28null T cells
from ACS patients with <2% CD28null T cells in peripheral blood. In
PBMCs, IL-15 significantly increased CD28null T-cell percentage at days 4
and 7 of culture (Supplementary material online, Figure S7), while in
Figure 1 Effect of IL-7 and IL-15 on CD28null T-cell expansion. PBMCs (A–C n = 10) or CD4þ T cells (D–F n = 14) from ACS patients with >3% circulat-
ing CD28null T cells were treated with 50 ng/mL IL-7 or IL-15 for 4 days. (A and D) Illustrative dot plots show CD28null T-cell percentage. (B and E)
Graphs show CD28null T-cell percentage, and (C and F) % increase in CD28null T cells (calculated as described in Methods) in untreated (w/o) and cyto-
kine-treated samples.*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (paired two-tailed Student’s t-test).






/cardiovascres/advance-article/doi/10.1093/cvr/cvaa202/5869524 by St G
eorge's U
niversity of London user on 23 O
ctober 2020
Figure 2 Effect of IL-7 and IL-15 on CD28null T-cell activation. PBMCs (A–D) or CD4þ T cells (E–H) from ACS patients were treated with 50 ng/mL IL-
7 or IL-15 for 4 days. The activation markers CD69 and HLA-DR were analysed on CD28null and CD28pos T cells. (A and E) Illustrative dot plots display
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.sorted CD4þ T cells both IL-7 and IL-15 increased CD28null T-cell per-
centage at days 7 and 11 (Supplementary material online, Figure S8).
3.3 IL-7 and IL-15 activate CD28null T cells
from ACS patients
Next, we sought the underlying mechanisms through which IL-7 and IL-
15 induced CD28null T-cell expansion. T-cell activation is a pre-requisite
for lymphocyte expansion and therefore, we quantified the activation
markers CD69 and HLA-DR following cytokine treatment. In both
PBMCs (Figure 2A–D) and sorted CD4þ T cells (Figure 2E–H), IL-7 and
IL-15 significantly increased the percentage of CD69-expressing and
HLA-DR-expressing CD28null T cells. In contrast, less marked changes
were observed in the control CD28þ T-cell subset following IL-7 or IL-
15 treatment (Figure 2). Inflammatory cytokines TNF-a, IL-1b, and IL-6
had no effect on CD69 or HLA-DR (Supplementary material online,
Figure S9), in line with the failure of these cytokines to induce CD28null
T-cell expansion.
We also investigated the effects of IL-7 and IL-15 on chemokine
receptors (CCR5, CXCR3) and memory markers (CD62L, CCR7,
CD45RA, CD45RO). IL-7 and IL-15 significantly up-regulated CCR5 ex-
pression on CD28null but not CD28þ T cells (Supplementary material
online, Figure S10A and B), while CXCR3 (Supplementary material online,
Figure S10C and D) and memory markers (Supplementary material on-
line, Figure S11) were unchanged.
3.4 IL-7 and IL-15 induce proliferation of
CD28null T cells from ACS patients
As IL-7 and IL-15 preferentially activate CD28null T cells (Figure 2), we in-
vestigated whether this resulted in proliferation of this cell subset, which
may explain CD28null T-cell expansion in ACS. For this purpose, sorted
CD4þ T cells were labelled with CFSE and cultured with IL-7 or IL-15;
proliferation, assessed as CFSE-dilution, was quantified (detailed in
Methods). There was little basal proliferation of CD28null and control
CD28þ T cells in the absence of IL-7 and IL-15 on days 5 and 7 of culture
(Figure 3, Supplementary material online, Figure S12). IL-7 and IL-15 in-
duced significant proliferation of CD28null T cells, while less proliferation
was noted in CD28þ T cells (Figure 3, Supplementary material online,
Figure S12).
3.5 IL-7 and IL-15 increase granzyme B
production and degranulation of CD28null
T cells from ACS patients
Next, we tested whether IL-7 and IL-15 affect CD28null T-cell function.
These cells characteristically produce the cytotoxic molecule GzB,
which endows them with cell lytic function, in stark contrast to conven-
tional CD28þ T cells that do not express this molecule.10 PBMCs (Figure
4A and B) or sorted CD4þ T cells (Figure 4C and D) from ACS patients
were treated with IL-7 or IL-15 for 4 days. In line with previous studies,10
most CD28null T cells (79% for PBMCs Figure 4A; 83% for CD4þ T cells
Figure 4C) expressed GzB at baseline. Both IL-7 and IL-15 significantly in-
creased the percentage of CD28null T cells expressing GzB (Figure 4A
and C). Moreover, IL-7 and IL-15 also increased the expression levels
(MFI) of GzB in CD28null T cells (Figure 4B and D). Next, we investigated
whether IL-7 and IL-15 affect the cytotoxic function of CD28null T cells
using a degranulation assay based on CD107a expression, as previously
described.10 Degranulation is triggered by T-cell receptor (TCR) stimu-
lation either by antigen recognition or, in in vitro assays by anti-CD3 anti-
bodies, and degranulating cells are identified by the expression of
CD107a (lysosomal associated membrane protein-1) on the cell sur-
face.20 Both IL-7 and IL-15 significantly up-regulated the anti-CD3-
induced degranulation of CD28null T cells (Figure 4E). Notably, IL-15 but
not IL-7 induced CD28null T-cell degranulation even in the absence of
anti-CD3 stimulation (Figure 4E).
3.6 IL-7 and IL-15 augment TNF-a and
IFN-c production by CD28null T cells from
ACS patients
CD28null T cells from ACS patients produce high levels of TNF-a and
IFN-c.10 As described previously,10 the percentage of TNF-a (Figure 5A)
and IFN-c (Figure 6A) producing cells was higher in resting CD28null
(TNF-a 94.3%; IFN-c 83.8%) than in the control CD28þ T-cell subset
(TNF-a 83%; IFN-c 12.8%). IL-7 or IL-15 did not change the percentage
of TNF-a-producing CD28null T cells (Figure 5A), however, TNF-a ex-
pression levels (MFI) significantly increased in both CD28null and CD28þ
T cells (Figure 5B). This was accompanied by a significant increase in
TNF-a in the culture medium of CD4þ T cells treated with IL-7 or IL-15
(Figure 5C). While IL-7 or IL-15 did not change the percentage of IFN-c-
producing CD28null T cells (Figure 6A), they markedly up-regulated IFN-c
expression levels (MFI) in CD28null T cells (Figure 6B), while this was less
prominent in control CD28þ T cells (Figure 6B). IFN-c levels in culture
medium from cytokine-treated CD4þ T cells were significant increased
by IL-15 (Figure 6C).
3.7 Blocking IL-7 and IL-15 signalling
prevents the expansion of CD28null T cells
from ACS patients
We next quantified IL-7 and IL-15 in plasma from ACS patients with
CD28null T-cell expansion (>3% CD28null T cells in peripheral blood)
and those without expansion of this cell subset (<2% CD28null T cells).
IL-7 and IL-15 levels were very low in plasma (Supplementary material
online, Figure S13A), in keeping with other studies that showed that these
cytokines are mainly expressed within cells and are barely detectable in
circulation.21,22 Mean IL-7 and IL-15 levels were higher in ACS patients
with CD28null T-cell expansion (IL-7: 8.08 pg/mL; IL-15: 11.01 pg/mL)
Figure 2 Continued
CD69 expression on CD28null and CD28pos T cells; dashed gates, isotype control antibody (Ctrl). (B and F) Graphs show the percentage of
CD69þ cells in untreated samples (w/o) or after cytokine treatment (B n = 8; F n = 10). (C and G) Illustrative dot plots display HLA-DR expres-
sion on CD28null and CD28pos T cells; dashed gates, isotype control antibody (Ctrl). (D and H) Graphs show the percentage of HLA-DRþ cells
in untreated samples (w/o) or after cytokine treatment (D n = 6; H n = 10). *P < 0.05;**P < 0.01; ns, not significant (two-tailed Wilcoxon
matched-pairs signed-rank test).
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..compared to ACS patients without expansion of this cell subset (IL-7:
3.36 pg/mL; IL-15: 3.53 pg/mL), but the differences were not significant
(Supplementary material online, Figure S13A). TNF-a, IL-1b, and IL-6
plasma levels were also low and similar in the two ACS groups
(Supplementary material online, Figure S13B). We hypothesized that dif-
ferences in signalling downstream of IL-7/IL-15 receptors may render
Figure 3 Effect of IL-7 and IL-15 on CD28null T-cell proliferation. CD4þ T cells from ACS patients were labelled with CFSE and cultured in the pres-
ence of 10 or 50 ng/mL IL-7 or IL-15 for 5 days. (A) Histograms illustrate CFSE fluorescence in CD28null and CD28pos T cells following treatment with
10 ng/mL IL-7 or IL-15. The percentage of cells that have proliferated (diluted CFSE) is indicated above the linear gates. (B) Proliferation of CD28null and
CD28pos T cells in untreated samples (w/o) and after cytokine treatment (n = 8). (C) Histograms show CFSE fluorescence of CD28null (blue) and
CD28pos (black) T cells treated with the indicated cytokines. *P < 0.05; **P < 0.01 (paired two-tailed Student’s t-test).
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Figure 4 Effect of IL-7 or IL-15 on the production of granzyme B and degranulation of CD28null T cells. PBMCs (A and B n = 8) or CD4þ T cells (C and
D n = 10) from ACS patients were treated with 50 ng/mL IL-7 or IL-15 for 4 days. (A and C) Illustrative dot plots show Granzyme B (GzB) expression in
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..CD28null T cells more sensitive to these cytokines. The IL-7 receptor
(IL-7R) has two chains: CD127 (the a chain, found only in IL-7R); and
CD132 (the c chain) that is shared with the IL-15 receptor.23 The IL-15
receptor (IL-15R) is composed of CD215 (unique to IL-15R; binds IL-15
but is not required for IL-15 signalling); CD122 (the b chain), which is
shared with the IL-2 receptor; and CD132.24 We assessed the baseline
expression of these chains in CD28null and in the control CD28þ T-cell
subset directly in fresh peripheral blood samples from ACS patients.
CD127 expression was lower in CD28null T cells compared to CD28þ T
cells (Figure 7A and B; P < 0.01). CD215 levels were very low in both cell
subsets (Figure 7A and B), in keeping with previous studies suggesting that
CD215 is not expressed in resting T cells but mainly expressed on cells
(e.g. dendritic cells) that produce and present IL-15 to responding T
cells.25 Notably, CD28null T cells expressed significantly higher levels of
CD122 compared to control CD28þ T cells (Figure 7A and B;
P < 0.0001), which may explain their increased responsiveness to IL-15.
CD132 expression was comparable in the two cell subsets (Figure 7A
and B). Next, we assessed the effect of IL-7 and IL-15 on the expression
of CD127 and CD215 (the chains involved in binding IL-7 and IL-15, re-
spectively) in CD28null and CD28þ T cells. IL-7 markedly down-
regulated CD127 in both CD28null and CD28þ T cells (Figure 7C and D).
Interestingly, IL-15 also significantly down-regulated CD127 but to a
lower extent compared to IL-7 (Figure 7C and D). In contrast, CD215
was significantly up-regulated in response to IL-7 and IL-15 mainly in
CD28null T cells (Figure 7E and F). IL-7 and IL-15 receptors signal prefer-
entially through JAK1/JAK3/STAT5, which associate with CD127,
CD122, and CD132.17,23,24,26 Baseline levels of phosphorylated-STAT5
were significantly higher in un-stimulated CD28null T cells from ACS
patients, compared to the control CD28þ T-cell subset (Figure 7G), indi-
cating higher basal activation of IL-7/IL-15 signalling in CD28null T cells.
Next, we blocked IL-7/IL-15 signalling with the JAK1/JAK3 selective in-
hibitor Tofacitinib,27,28 which significantly inhibited CD28null T-cell ex-
pansion, while not affecting CD28þ T cells (Figure 7H).
4. Discussion
Here, we show that IL-7 and IL-15 cytokines augment the number and
function of CD28null T cells from patients with ACS. We demonstrate
that IL-7 and IL-15 trigger expansion of CD28null T cells, while inflamma-
tory cytokines TNF-a, IL-1b, and IL-6 have no effect. The mechanisms
underlying CD28null T-cell expansion are preferential activation and pro-
liferation of CD28null T cells by IL-7 and IL-15. These cytokines increase
the cytotoxic function of CD28null T cells (GzB production and degranu-
lation) and the production of IFN-c. We provide further mechanistic
insights showing marked differences in baseline levels of CD127 and
CD122 (component chains of IL-7 and IL-15 receptors) and increased
baseline phosphorylation of STAT5 in CD28null T cells compared to
their control CD28þ T-cell subset. Blockade of IL-7/IL-15 signalling with
a JAK1/JAK3 selective inhibitor prevents the expansion of CD28null T
cells from ACS patients (summarized in the Graphical Abstract).
Inflammatory CD28null T cells expand in the circulation and athero-
sclerotic plaques of patients with ACS.6,7 Notably, ACS patients with ex-
pansion of the CD28null T-cell subset have increased risk for recurrent
severe acute coronary events and poorer prognosis compared to ACS
patients without CD28null T-cell expansion.9 This study also showed that
an increase in CD28null T-cell frequency is an independent predictor of
future acute coronary events in ACS patients.9 The precise mechanisms
driving the expansion of CD28null T cells in ACS are unknown. Here, we
show that the cytokines IL-7 and IL-15 are involved in the expansion of
CD28null T cells from ACS patients, while inflammatory cytokines TNF-
a, IL-1b, and IL-6 did not have an effect. However, inflammatory cyto-
kines TNF-a, IL-1b, and IL-6 are important in atherosclerosis pathogene-
sis, as recently shown by the CANTOS trial, which found that specifically
targeting inflammation (IL-1b inhibition) improves clinical outcomes in
patients with a previous myocardial infarction.16 Our findings underscore
that several cytokines and inflammatory networks may be at work in
ACS patients, and that a better characterization of patients’ inflammatory
status is needed to improve the efficacy of anti-inflammatory therapies in
ACS. Moreover, as CD28null T cells have been exclusively identified in
humans and do not exist in mice, this precludes interrogation of their
roles in atherosclerosis using currently available animal models. Our
work emphasizes the need to investigate inflammation and immune
responses in patients with ACS as key information on the cellular and
molecular pathophysiology of human CAD may be missed in murine
models.
Strikingly, IL-7 and IL-15 drove the activation and proliferation of
CD28null T cells from ACS patients in the absence of T-cell receptor
(TCR)-derived signals (i.e. antigen stimulation). A possible explanation is
that CD28null T cells share features with natural killer (NK) cells29,30 that
also expand in response to IL-15 in the absence of antigen-dependent
stimulation. IL-15 has central roles in the development, maintenance, ac-
tivation, and effector function of NK cells (cytotoxicity, IFN-c produc-
tion).31 Indeed, CD28null T cells express NK cell receptors and exhibit
NK-like effector functions such as expression of cytotoxic molecules
(GzB, perforin), cytotoxicity, and IFN-c production,29,30 which may ex-
plain their response to IL-15. In contrast to IL-15, IL-7 does not increase
NK cell activation, cytotoxicity, and IFN-c production.32 Nevertheless,
IL-7 triggered activation and markedly augmented the cytotoxic and cy-
tokine production function of CD28null T cells from ACS patients.
Moreover, IL-7 had comparable effects to IL-15 on CD28null T-cell ex-
pansion, activation, and function, although only IL-15 directly triggered
Figure 4 Continued
CD28null T cells; dashed gates, isotype control antibody (Ctrl). The graphs depict percentages of GzBþ cells in untreated samples (w/o) and after
cytokine treatment. (B and D) Histograms showing GzB expression in CD28null T cells; dashed histograms, isotype control antibody. The num-
bers indicate the mean fluorescence intensities (MFI) in cells cultured alone (w/o) or with cytokines. The graphs show GzB levels (MFI) in
untreated and cytokine-treated cells. **P < 0.01 (two-tailed Wilcoxon matched-pairs signed-rank test). a.u., arbitrary units. (E) CD4þ T cells
(n = 7) were cultured alone (w/o) or with 50 ng/mL IL-7 or IL-15 for 4 days. On day 4, cells were stimulated with anti-CD3 antibodies (aCD3) for
4 h as indicated, and degranulation was quantified with CD107a (detailed in Methods). Illustrative dot plots show CD107a expression in
CD28null T cells; dashed gates, isotype control antibody (Ctrl); the graph displays the percentage of CD28null T cells expressing CD107a
(mean±SEM). *aP < 0.05 (aCD3 only or IL-15 only vs. w/o); ****bP < 0.0001 (aCD3þIL-7 or aCD3þIL-15 vs. aCD3) (two-way ANOVA with
post-test Tukey for multiple comparisons).
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..CD28null T-cell degranulation in the absence of anti-CD3 stimulation.
Notably, our data that IL-7 and IL-15 drive CD28null T-cell activation,
proliferation, and function independently of TCR signals indicate that
these cytokines may sustain the expansion and functions of these lym-
phocytes in the absence of antigen restimulation in ACS. IL-7 and IL-15
also increased CCR5 expression on CD28null T cells from ACS patients.
CCR5 has been suggested to regulate tissue homing to the aorta of Th1
CD4þ T cells.33 This suggests that IL-7 and IL-15 may enhance CD28null
T-cell homing to atherosclerotic plaques, which will be investigated in fu-
ture studies.
IL-7 and IL-15 have been implicated in several autoimmune disorders,
in particular in RA where these cytokines are identified in synovial fluid
and tissue.18,19 The effect of IL-7 on CD28null T cells has not been previ-
ously studied in any disease, while the effect of IL-15 on CD28null T cells
has been investigated in multiple sclerosis, elderly individuals, and rheu-
matoid arthritis.34–36 Whether IL-7 and IL-15 have a role in atherosclero-
sis is less well established. Expression of IL-15 in lipid-rich human
atherosclerotic plaques associated with increased T-cell infiltration and
plaque-derived T-cell lines proliferated to IL-15 in vitro.35 In addition, IL-
15 induced the development of atherosclerotic plaques in ldlr-/- mice,
though this is independent of CD28null T cells as this cell subset is not de-
scribed in mice.37 While a previous study suggested that plasma IL-7 is
raised in unstable or stable angina patients compared to healthy sub-
jects,38 others reported that IL-7 and IL-15 are predominantly expressed
Figure 5 Effect of IL-7 or IL-15 on the production of TNF-a by CD28null T cells. CD4þ T cells (n = 10) from ACS patients were treated with 50 ng/mL
IL-7 or IL-15 for 3 days. (A) Illustrative dot plots and graphs display the percentage of TNF-aþCD28null (top) and TNF-aþCD28pos (bottom) T cells in
untreated samples (w/o) and after cytokine treatment; dashed gates, isotype control antibody (Ctrl). (B) The histograms and graphs show TNF-a expres-
sion levels by CD28null (top) and CD28pos (bottom) T cells with or without (w/o) cytokine treatment; dashed histograms, isotype control antibody; the
numbers indicate the mean fluorescence intensities (MFI) for each treatment. (A and B) *P < 0.05; **P < 0.01; ns, not significant (two-tailed Wilcoxon
matched-pairs signed-rank test). a.u., arbitrary units. (C) The bar graph shows TNF-a levels in media from CD4þ T cells (n = 9) cultured with cytokines as
above (mean±SEM). **P < 0.01 (one-way ANOVA with post-test Bonferroni for multiple comparisons).
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.within cells (macrophages, dendritic cells, epithelial, and stromal cells)
with barely detectable circulating stores.21,22 We found low plasma lev-
els of IL-7 and IL-15 in ACS patients, suggesting that CD28null T-cell ex-
pansion in ACS may be driven by IL-7 and IL-15 produced locally in
atherosclerotic plaques or artery-associated lymphoid tissue. Our data
that baseline expression of CD127 was lower in CD28null T cells from
ACS patients compared to control CD28þ T cells, suggest down-
regulation of CD127 by in vivo exposure to IL-7/IL-15. This is supported
by our in vitro findings that CD127 is down-regulated in CD28null T cells
following IL-7 and IL-15 treatment. Additionally, the higher basal levels of
phosphorylated-STAT5 in CD28null T cells indicate higher basal
activation of IL-7/IL-15 signalling in vivo. The increased responsiveness of
CD28null T cells to IL-15 is also supported by our new data that CD28null
T cells from ACS patients have higher baseline expression of CD122,
the b-chain of IL-15 receptor. Moreover, IL-7 and IL-15 markedly up-
regulated the expression of CD215 (the IL-15 receptor-specific chain) in
CD28null T cells in vitro, which would further augment their responsive-
ness to IL-15.
ACS patients with CD28null T-cell expansion have increased risk for
recurrent ACS and poor prognosis9 and may benefit from strategies that
prevent expansion of these cells such as IL-7/IL-15 neutralization or sig-
nalling blockade. Indeed, we include novel data that Tofacitinib (a
Figure 6 Effect of IL-7 or IL-15 on the production of IFN-c by CD28null T cells. CD4þ T cells from ACS patients (n = 10) were treated with 50 ng/mL
IL-7 or IL-15 for 3 days. (A) Illustrative dot plots and graphs display the percentage of IFN-cþCD28null (top) and IFN-cþCD28pos (bottom) T cells in
untreated samples (w/o) and after cytokine treatment; dashed gates, isotype control antibody (Ctrl). (B) The histograms and graphs show IFN-c expres-
sion levels by CD28null (top) and CD28pos (bottom) T cells with or without (w/o) cytokine treatment; dashed histograms, isotype control antibody; the
numbers indicate the mean fluorescence intensities (MFI) for each treatment. (A and B) *P < 0.05; **P < 0.01; ns, not significant (two-tailed Wilcoxon
matched-pairs signed-rank test). a.u., arbitrary units. (C) The bar graph shows IFN-c levels in media from CD4þ T cells (n = 9) cultured with cytokines as
above (mean±SEM). **P < 0.01; ns, not significant (one-way ANOVA with post-test Bonferroni for multiple comparisons).
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..selective JAK1/JAK3 inhibitor that blocks IL-7/IL-15 signalling) prevents
the expansion of CD28null T cells from ACS patients. This effect of
Tofacitinib on CD28null T cells has not been explored in other dis-
eases. Of interest, Tofacitinib is used in patients with RA and active
psoriatic arthritis39,40 and has been recently approved for use in ul-
cerative colitis.41
A potential limitation of this study is that CD28null T cells have been
exclusively identified in humans and do not exist in mice precluding
Figure 7 Blockade of IL-7/IL-15 signalling with the JAK1/JAK3 selective inhibitor Tofacitinib prevents CD28null T-cell expansion. Fresh peripheral blood
samples from ACS patients (n = 10) were stained with CD4, CD28, CD122, CD127, CD132, and CD215 monoclonal antibodies. Illustrative dot plots (A)
and graphs (B) show the percentage of CD28null and CD28þ T cells expressing CD122, CD132, CD127, and CD215; dashed gates, isotype control anti-
body (Ctrl). CD4þ T cells from ACS patients (n = 10) were cultured alone (w/o) or treated with 50 ng/mL IL-7 or IL-15 for 3–4 days and expression of
CD127 and CD215 was analysed on CD28null and CD28pos T cells. Illustrative dot plots and graphs display the percentage of CD127þ cells (C and D),
and CD215þ cells (E and F) in CD28null and CD28pos T cells; dashed gates, isotype control antibody (Ctrl). (G) Baseline levels of phosphorylated STAT5
(pSTAT5) were quantified using the PhosFlow Method (described in Methods); black and dashed histograms, isotype control antibody; the numbers indi-
cate the mean fluorescence intensity (MFI). Illustrative histograms and bar graph display the expression levels (MFI) of pSTAT5 in CD28null and CD28pos
T cells (n = 6; mean±SEM). (H) CD4þ T cells from ACS patients (n = 10) were cultured alone (w/o) or treated with 50 ng/mL IL-7 or IL-15 in the presence
or absence of 100 nM Tofacitinib (Tofa) for 7 days. Graphs show the fold change in the percentage of CD28null or CD28pos T cells (mean±SEM).
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (B) Two-tailed Mann–Whitney test; (D and F) two-tailed Wilcoxon matched-pairs signed-rank test;
(G) paired two-tailed Student’s t-test; (H) two-way ANOVA with post-test Bonferroni for multiple comparisons.
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interrogation of their roles in atherosclerosis using currently available an-
imal models. Therefore our study is an in-depth ex vivo analysis of fresh
peripheral blood and primary cells from ACS patients. However, our
work also highlights the need to investigate inflammation and immune
responses in patients with ACS as key mechanisms of the cellular patho-
physiology of human CAD may be missed in murine models.
Conclusions
This study provides new mechanistic insights and identifies novel roles
for IL-7 and IL-15 cytokines in CD28null T-cell expansion and function in
ACS. Our new findings suggest potential clinical applications of IL-7/IL-
15 blockade in ACS patients with CD28null T-cell expansion for targeted
modulation of the inflammation mediated by these cells.
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38. Damaås JK, Wæhre T, Yndestad A, Otterdal K, Hognestad A, Solum NO, Gullestad
L, Frøland SS, Aukrust PL. Interleukin-7-mediated inflammation in unstable angina:
possible role of chemokines and platelets. Circulation 2003;107:2670–2676.
39. Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K,
Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS,
Adams L, Ally MM, Du Plooy MC, Louw IC, Nayiager S, Nel CB, Nel D, Reuter H,
Soloman AS; ORAL Strategy investigators. Efficacy and safety of tofacitinib mono-
therapy, tofacitinib with methotrexate, and adalimumab with methotrexate in
patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind,
head-to-head, randomised controlled trial. Lancet 2017;390:457–468.
40. Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E,
Wang C, Menon S, Hendrikx T, Kanik KS. Tofacitinib for psoriatic arthritis in patients
with an inadequate response to TNF inhibitors. N Engl J Med 2017;377:1525–1536.
41. Sandborn WJ, Su C, Panés J. Tofacitinib as induction and maintenance therapy for ul-
cerative colitis. N Engl J Med 2017;376:1723–1736.
Translational perspective
CD28null T cells expansion in ACS patients is an independent predictor of future acute coronary events and poor prognosis. The precise mecha-
nisms underlying CD28null T-cell expansion in ACS remain elusive. We show that IL-7 and IL-15 cytokines cause expansion of CD28null T cells from
ACS patients by triggering activation and proliferation, and augment the cytotoxic function of these cells and production of inflammatory cytokines.
We demonstrate that CD28null T-cell expansion is inhibited by Tofacitinib that specifically blocks IL-7/IL-15 signalling. Further dissection of the roles
of IL-7/IL-15 may lead to more effective and specific anti-inflammatory therapies in ACS.
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